COBAS EGFR MUTATION TEST
Roche · Decision date May 14, 2013
What did the FDA approve?
FDA PMA P120019 was approved for the cobas® EGFR Mutation Test. The record describes the device as a real-time PCR assay for qualitative detection of EGFR exon 19 deletions and exon 21 (L858R) substitution mutations in DNA from formalin-fixed paraffin-embedded human NSCLC tumor tissue. That is the original PMA scope stated here; the source does not describe a supplement or any change to that scope.
The statement also gives the intended-use wording: the test is an aid in selecting patients with metastatic NSCLC for whom Tarceva® (erlotinib) is indicated. It does not provide clinical performance data, trial results, or a broader indication beyond that language, so those points remain unknown from this record.
FDA approval order statement
APPROVAL FOR THE COBAS EGFR MUTATION TEST. THE COBAS EGFR MUTATION TEST IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OFTHE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPET) HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN SELECTING PATIENTS WITH METASTATIC NSCLC FOR WHOM TARCEVA (ERLOTINIB), AN EGFR TYROSINE KINASE INHIBITOR (TK1), IS INDICATED. SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- May 14, 2013
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120019
- Regulatory pathway
- Premarket approval application
- Applicant
- Roche
- Product code
- OWD
- Decision code
- APPR
- Decision date
- May 14, 2013
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P120019 received
Application receipt date recorded by FDA.
P120019 · FDA decision
APPR
P120019/S044 · Related supplement
cobas EGFR Mutation Test, v2.0
P120019/S045 · Related supplement
Roche cobas EGFR Mutation Test, v2.0
Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588
Sources and methodology
- Original FDA record: P120019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



